Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immucell ( (ICCC) ) just unveiled an update.
ImmuCell Corporation, an animal health biologics specialist focused on improving dairy and beef calf health through its First Defense® hyperimmune colostrum product line, is expanding its leadership capabilities as it targets broader U.S. and international markets. The Portland, Maine-based company develops and markets practical, science-based solutions aimed at reducing scour-related mortality in neonatal calves and supporting long-term performance for producers.
On March 18, 2026, ImmuCell announced that Kathy Turner will join its Board of Directors effective April 1, 2026, replacing long-serving director Steven Rosgen, who is retiring after eight years of service. Turner, a former Elanco Animal Health board member with senior leadership experience at IDEXX Laboratories and Abbott Laboratories, will chair the Compensation and Stock Option Committee and sit on the Audit Committee, bolstering ImmuCell’s commercial and international expertise as it seeks to expand the reach of First Defense® in the U.S. and global animal health markets.
The board change, first set in motion when Rosgen notified the company in February 2026 of his decision not to stand for re-election, reflects a planned transition rather than a governance disruption. Management highlighted Turner’s track record in scaling international businesses and her deep industry network as strategic assets expected to support ImmuCell’s growth ambitions in the highly competitive animal health sector and to enhance oversight of its compensation and financial governance frameworks.
The most recent analyst rating on (ICCC) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
The score is held back primarily by weaker financial performance quality (revenue contraction, ongoing net losses, and uncertain/weak cash-flow data) despite reduced leverage. Technical indicators are neutral and provide limited support. The latest earnings call adds a modest positive tilt due to improved margins, operating income, and credible capacity plans, but valuation remains pressured by loss-making status and no dividend support.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
ImmuCell Corporation is an animal health biologics company serving the dairy and beef industries with science-based solutions to improve the survivability, health and long-term performance of calves. Its primary product line, First Defense®, is a hyperimmune colostrum-based treatment that provides orally delivered antibodies against key viral and bacterial causes of scours in neonatal calves, a leading cause of mortality worldwide.
The company develops, manufactures and markets these products with a focus on improving calf health and productivity in both U.S. and international markets. By targeting prevalent diseases in newborn dairy and beef calves, ImmuCell aims to offer practical tools that enhance productivity and economic outcomes for producers while strengthening its position in the global animal health market.
Average Trading Volume: 24,479
Technical Sentiment Signal: Hold
Current Market Cap: $54.73M
Learn more about ICCC stock on TipRanks’ Stock Analysis page.